Why Diversity in Clinical Trials — and Among Those Who Lead Them — Matters More Than Ever

It is imperative that representation is more than a “nice-to-have.” When the medical field reflects the communities it serves, across race, ethnicity, and gender, patients thrive.

Sonja Hughes, M.D.

Vice President of Community Health, Susan G. Komen

Regarded as the backbone of medical progress, clinical trials can be traced back to the 18th century. They determine which drugs reach the market, which therapies become standard care, and ultimately which lives are saved. But for too long, those trials have not fully represented the people they’re designed to help. Cancer clinical trial enrollment by adults in the United States is less than five percent. Of these participants, fewer than 10 percent are members of racial or ethnic communities who often face higher breast cancer mortality rates.

When research excludes diverse populations across race, ethnicity, gender, and socioeconomic background, the science is incomplete — and patients pay the price.

The solution requires intention

Different populations respond uniquely to treatments because of variables in genetics, lifestyle and health risks. If participants in a study are overwhelmingly white and male, can we truly know how safe or effective that treatment will be for women, Black or Latino patients, or others who historically face worse health outcomes? The answer is too often “no.”

Underrepresentation is not only a numbers problem but a health equity crisis that can be turned around through intentional practice. Every gap in evidence widens disparities in who benefits fastest from scientific breakthroughs. Inclusive research isn’t optional. It’s a moral and scientific imperative that ensures medicine works for everyone. But diversity must extend beyond trial participants. It’s equally crucial among the researchers designing the studies, choosing what questions to ask and determining how results are interpreted. Currently, women make up a strong share — around half — of non-physician cancer researchers, including those in fields like breast cancer, which one might assume would naturally be female-led. Yet women researchers are still underrepresented in senior and decision-making roles: fewer lab heads, fewer principal investigators, and fewer senior authors on high-impact publications. All critical roles in the pathway to cure diseases.

The ripple effect

These leadership gaps are not only a matter of fairness; they shape scientific priorities and ultimately lifesaving outcomes. What research gets funded, which hypotheses are pursued, and which patient needs are centered often reflect who is in the room and, most importantly, who isn’t.

There is a persistent drop-off where women enter the field but struggle to advance, limiting the innovation and diverse knowledge desperately needed in cancer and across medicine. According to a 2022 BMJ Open study, women were leaving academic medicine due to not enough institutional support, access to relatable mentors, pregnancy, and maternity leave.

Luckily, some programs are in place to bridge such gaps. For example, Susan G. Komen’s ASPIRE grant is designed to strengthen diversity in the breast cancer research workforce. It provides established breast cancer researchers with additional funding to support researchers from communities that have been historically underrepresented and marginalized in this critical area.

Correcting course

By investing in these promising scientists early in their careers, we can aim to build a diverse, highly skilled next generation of leaders who represent the communities we serve and are committed to ending breast cancer forever.

To build a more just health care system, action must be taken on both fronts: expand representation in clinical trials and dismantle barriers preventing women researchers from leading them. That means investing in recruitment from underserved communities, supporting mentorship and advancement for women scientists, and demanding transparency in who participates along with who leads.

Representation is not a box to check. It’s the foundation of trust, equity, and scientific excellence. Because when the future of medicine reflects the full capacity of humanity, everyone has a better chance to live.

The post Why Diversity in Clinical Trials — and Among Those Who Lead Them — Matters More Than Ever appeared first on Education and Career News.